You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 23, 2025

AMJEVITA Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: AMJEVITA
High Confidence Patents:0
Applicants:1
BLAs:1
Pharmacology for AMJEVITA
Mechanism of ActionTumor Necrosis Factor Receptor Blocking Activity
Established Pharmacologic ClassTumor Necrosis Factor Blocker
Chemical StructureAntibodies, Monoclonal
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for AMJEVITA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for AMJEVITA Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for AMJEVITA Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Biologic Drug: AMJEVITA

Introduction

AMJEVITA, Amgen's biosimilar to AbbVie's blockbuster drug Humira, has been a highly anticipated entry into the U.S. biologics market. Since its launch in January 2023, the drug has faced several challenges and opportunities that have shaped its market dynamics and financial trajectory.

Launch and Initial Market Impact

AMJEVITA was the first adalimumab biosimilar to enter the U.S. market, following its FDA approval in 2016. However, its launch was delayed due to AbbVie's aggressive patent protection strategies[3].

Upon launch, AMJEVITA had a brief period of exclusivity, competing directly with Humira for six months. During this time, Amgen adopted a dual-pricing strategy, offering AMJEVITA at two price points: one at 55% below Humira's list price and another at 5% below[1].

Sales Performance in the U.S.

The initial sales figures for AMJEVITA were promising, with $51 million in revenue in the first quarter of 2023. However, this momentum was short-lived. In the second quarter, U.S. sales dropped to $19 million, a 63% decline from the previous quarter. This drop was attributed to inventory drawdown after the initial launch stockpiling and changing payer behavior[1][4].

Global Sales Performance

In contrast to the U.S. market, AMJEVITA (marketed as Amgevita outside the U.S.) has shown significant growth globally. In the second quarter of 2023, global sales increased by 29% year-over-year, with $131 million in sales outside the U.S.[1][4].

Payer Dynamics and Rebate Impact

One of the critical factors affecting AMJEVITA's uptake in the U.S. is the complex rebate dynamics managed by pharmacy benefit managers (PBMs). Despite the significant discount offered by AMJEVITA, PBMs have favored the more expensive version due to rebate structures, which has hindered the biosimilar's adoption[1].

Competitive Landscape

The biologics market, particularly for adalimumab, is becoming increasingly competitive. Multiple biosimilars are expected to launch in the coming months, which will further shape the market dynamics. Amgen anticipates that the product mix and payer negotiations will continue to evolve, potentially driving greater utilization of biosimilars in 2024[1].

Financial Impact on Amgen

The performance of AMJEVITA has had a mixed impact on Amgen's financials. While the drug's U.S. sales have been disappointing, global sales have been robust. Amgen's overall revenue for the second quarter of 2023 was $7 billion, a 6% increase year-over-year, driven by strong performances from other products like Repatha and Prolia[1].

Guidance and Projections

For the full year 2024, Amgen has adjusted its revenue projections to a range of $32.8 billion to $33.8 billion, reflecting both the challenges faced by AMJEVITA and the overall performance of its product portfolio. The company also expects GAAP EPS in the range of $6.57 to $7.62 and non-GAAP EPS in the range of $19.10 to $20.10[2].

Impact of Horizon Acquisition

Amgen's financial trajectory is also influenced by its acquisition of Horizon Therapeutics, expected to be completed by the end of 2024. This acquisition is not included in the current revenue projections but is anticipated to add significant value to Amgen's portfolio in the future[1][2].

Market Savings and Clinical Impact

The introduction of biosimilars like AMJEVITA is expected to drive significant cost savings in the healthcare sector. According to IQVIA, biosimilars could save the U.S. healthcare system up to $180 billion by 2027, despite an overall spending increase. This has already led to an additional 150 million days of therapy, enhancing patient access to biologic treatments[3].

Industry Expert Insights

Industry experts and company executives have provided insights into the challenges and opportunities facing AMJEVITA. Murdo Gordon, Amgen's chief of global commercial operations, highlighted the new payer behavior and inventory dynamics affecting sales. Richard Gonzalez, AbbVie's CEO, noted that Humira is competing effectively against biosimilar offerings, but acknowledged the impact of biosimilar competition on Humira's sales[1][4].

Future Outlook

As the biosimilar market continues to evolve, AMJEVITA's performance is expected to stabilize and potentially improve. Amgen is awaiting the next payer negotiation cycle in 2024, which could drive greater utilization of biosimilars. The global market, particularly outside the U.S., remains a strong growth area for AMJEVITA[1].

Key Takeaways

  • Launch and Initial Sales: AMJEVITA launched in January 2023 with initial U.S. sales of $51 million, but saw a 63% decline in the second quarter.
  • Global Performance: Global sales of AMJEVITA have been strong, with a 29% year-over-year increase.
  • Payer Dynamics: Complex rebate structures have hindered AMJEVITA's adoption in the U.S.
  • Financial Impact: Mixed financial impact with strong overall revenue but disappointing U.S. sales for AMJEVITA.
  • Guidance and Projections: Adjusted revenue projections for 2024 reflect both challenges and strong performances from other products.
  • Market Savings: Biosimilars are expected to drive significant cost savings and enhance patient access.

FAQs

What is AMJEVITA, and when was it launched in the U.S.?

AMJEVITA is Amgen's biosimilar to AbbVie's Humira, launched in the U.S. on January 31, 2023.

Why did AMJEVITA's U.S. sales decline significantly in the second quarter of 2023?

The decline was attributed to inventory drawdown after the initial launch stockpiling and changing payer behavior due to complex rebate dynamics.

How has AMJEVITA performed globally?

Globally, AMJEVITA (marketed as Amgevita outside the U.S.) has shown strong growth, with a 29% year-over-year increase in sales.

What is the expected impact of biosimilars on the healthcare sector?

Biosimilars are expected to save the U.S. healthcare system up to $180 billion by 2027 and have already led to an additional 150 million days of therapy.

How does the acquisition of Horizon Therapeutics impact Amgen's financial projections?

The acquisition is expected to add significant value but is not included in the current revenue projections for 2024.

References

  1. FiercePharma: Amgen's hyped Humira biosimilar generates just $19M in Q2 sales[1].
  2. InvestingNews: AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS[2].
  3. Drug Topics: A Biosimilar Wave Looms Large Over US Biologics Market[3].
  4. AJMC: Amgen Announces $19M in Q2 Revenue From Amjevita; Humira Down 26% in US[4].
  5. PR Newswire: AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS[5].
Last updated: 2024-12-19

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.